title: Improved patient selection for TAH implantation.
abstract: Patient selection and optimal timing for implantation are unsettled issues in candidates for a bridge to cardiac transplantation. A prospective evaluation of a strategy based on enoximone (E) given IV, in addition to sympathomimetic drugs, permitting to buy time, and delay by hours or days the decisions, has been performed from 1985 to 1988. Thirty-four patients in cardiogenic shock with hemodynamical criteria for TAH implantation have been included: Cl was 1.8 +/- 0.2 L/min/m2 PCWP 29 +/- 7 mmHg, diuresis less than 20 ml/hr. The protocol permitted to postpone decisions of implantation in 30 cases. The 4 unresponsive patients were implanted immediately with TAH (3) or VAD (1). Three were transplanted, two successfully. For 30, time given permitted discovery of hidden contraindications to transplantation in 17 patients. In 13, indication for transplantation was confirmed and performed in 11 within 6 hrs to 8 days (survival 64%). In two, sudden deterioration led to an unsuccessful TAH implantation. Multifactorial analysis showed that a 50% rise in Cl together with a 50% drop in PCWP, a 50% drop in PVR 30 min after IV E has a high predictive value of survival. These data suggest that enoximone IV bolus given in addition to maximal sympathomimetics to patients in cardiogenic shock reduces by 88% the need for TAH or VAD. It also permits a better selection of the candidates.
authors.affiliation: Department of Surgical Research, C.H.U. Henri Mondor, Créteil, France.
authors.forename: D
authors.initials: D
authors.lastname: Loisance
authors.forename: J L
authors.initials: JL
authors.lastname: Dubois Rande
authors.forename: P
authors.initials: P
authors.lastname: Deleuze
authors.forename: C
authors.initials: C
authors.lastname: Benvenuti
authors.forename: P
authors.initials: P
authors.lastname: Dervanian
authors.forename: S
authors.initials: S
authors.lastname: Brunet
authors.forename: M L
authors.initials: ML
authors.lastname: Hillion
authors.forename: A
authors.initials: A
authors.lastname: Castaigne
authors.forename: J P
authors.initials: JP
authors.lastname: Cachera
mesh_terms: D000328:Adult; D002316:Cardiotonic Agents / Q000008:administration & dosage; D017335:Enoximone; D005260:Female; D006333:Heart Failure / Q000601:surgery*; D016027:Heart Transplantation; D006354:Heart, Artificial; D006353:Heart-Assist Devices; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D011474:Prosthesis Design; D012017:Referral and Consultation; D012770:Shock, Cardiogenic / Q000601:surgery
chemical_list: D002316:Cardiotonic Agents; D007093:Imidazoles; D017335:Enoximone